By Dr Mark William Donoghoe

Journal articles

Ting R; Davis T; Drury P; Donoghoe M; Rajamani K; Best J; Kesaniemi Y; Keech A, 2011, 'Cardiovascular Risk, Renal Status and Fenofibrate Safety in the FIELD Study', Heart, Lung and Circulation, 20, pp. S202 - S202, http://dx.doi.org/10.1016/j.hlc.2011.05.497

Donoghoe MW; Gebski V, 2011, 'Impact of the censoring distribution on time-to-event problems in the presence of competing risks', Trials, 12, http://dx.doi.org/10.1186/1745-6215-12-s1-a140

Rajamani K; Donoghoe M; Li L; Ting R-D; Colman P; Scott R; Laakso M; Keech A, 2010, 'FENOFIBRATE REDUCES PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES: THE FENOFIBRATE INTERVENTION AND EVENT LOWERING IN DIABETES (FIELD) STUDY', ATHEROSCLEROSIS SUPPLEMENTS, 11, pp. 219 - 220, http://dx.doi.org/10.1016/S1567-5688(10)71046-1

Ting R-D; Davis TME; Drury PL; Donoghoe M; Rajamani K; Best JD; Kesaniemi YA; Keech AC, 2010, 'MS544 CARDIOVASCULAR AND RENAL SAFETY OF FENOFIBRATE IN THE FIELD STUDY', Atherosclerosis Supplements, 11, pp. 219 - 219, http://dx.doi.org/10.1016/s1567-5688(10)71044-8

Sullivan D; Donoghoe M; Simes J; George J; Keech T, 2009, 'Abstract: P496 LONG-TERM FENOFIBRATE USE IS ASSOCIATED WITH REDUCED PREVALENCE OF LIVER ENZYME ELEVATION IN THE FIELD STUDY', Atherosclerosis Supplements, 10, pp. e809 - e809, http://dx.doi.org/10.1016/s1567-5688(09)70791-3

Conference Papers

Body A; Wakefield C; Vi TTL; Donoghoe M; Bolanos NAF; Anazodo A; Ho C; Grech L; Ahern ES; Segelov E, 2022, 'Patient-reported toxicity and quality of life following Sars-CoV-2 vaccination in adults and children with cancer', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000891791500044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mitchell P; Siva S; Kok PS; O'Byrne K; Yeung A; Livingstone A; Donoghoe M; Yip S; Stockier MR, 2017, 'NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.9097

Stanton KM; Rao SD; Assimes T; Wang B-Y; McGee S; Harada RK; Wilson A; Narasimhan B; Donoghoe M; Brown C; Keech A; Olin JW; Cooke JP; Ng MK, 2012, 'Plasma Asymmetric Dimethylarginine Levels Correlate with Peripheral Arterial Disease Severity but not Coronary Artery Disease', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208885006387&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ting R; Davis TME; Jenkins AJ; Drury PL; Donoghoe MW; Rajamani JK; Kesaniemi AY; Best JD; Keech AC, 2011, 'Association of renal status and cardiovascular risk, and safety of fenofibrate in renal impairment in the FIELD study of 9,795 subjects with type 2 diabetes', in DIABETOLOGIA, SPRINGER, PORTUGAL, Lisbon, pp. S24 - S24, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), PORTUGAL, Lisbon, 12 September 2011 - 16 September 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307671300042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Keech AC; Rajamani JK; Best JD; Hankey G; Donoghoe MW; Li L; Jenkins AJ; Ting R; Davis TME; Phillips P; Barter P, 2011, 'Predictors of peripheral neuropathy and effects of fenofibrate among 9,795 subjects with type 2 diabetes: the fenofibrate intervention and event lowering in diabetes (FIELD) study', in DIABETOLOGIA, SPRINGER, PORTUGAL, Lisbon, pp. S81 - S82, presented at 47th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), PORTUGAL, Lisbon, 12 September 2011 - 16 September 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000307671300181&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ting R; Donoghoe M; Jenkins AJ; Hedley J; Rajamani K; Drury PL; Davis TME; Celermajer D; Simes RJ; Keech AC, 2011, 'Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes mellitus and renal impairment - the FIELD study', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 323 - 324, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208702703033&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Keech AC; Alicia J; Whiting M; Barter P; Sullivan DR; Donoghoe M; Januszewski A; Karschimkus C; Blankenberg S; Simes J; Scott R; Laakso M; Taskinen M-R; Best JD, 2010, 'Novel Cardiovascular Risk Factor Prediction of Cardiovascular Events in the (Type 2 Diabetes) FIELD Study and Effects of Fenofibrate', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208231602961&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sullivan D; Donoghoe M; Simes J; George J; Keech T, 2009, 'LONG-TERM FENOFIBRATE USE IS ASSOCIATED WITH REDUCED PREVALENCE OF LIVER ENZYME ELEVATION IN THE FIELD STUDY', in ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER IRELAND LTD, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000207957101492&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Posters

Nowak A; Kok P-S; Livingstone A; Lesterhuis WJ; Yip S; Donoghoe M; Lam W-S; Stockler M, 2017, 'DREAM - A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In', Vol. 12, pp. S1086 - S1087, http://dx.doi.org/10.1016/j.jtho.2016.11.1518

Conference Abstracts

Nagabushan S; Hamayun M; Fardell JE; Donoghoe M; Bland E; Bye A; Jacobson E; Manoharan N; Ziegler DS; McLoone JK; Johnson AM; Cohn RJ, 2023, 'LGG-11. COGNITIVE, ACADEMIC, AND QUALITY OF LIFE OUTCOMES IN SURVIVORS OF PEDIATRIC LOW-GRADE GLIOMA: CHALLENGING THE ‘BENIGN TUMOR’ PERCEPTION', in Neuro-Oncology, Oxford University Press (OUP), Vol. 25, pp. i57 - i58, http://dx.doi.org/10.1093/neuonc/noad073.221

McLoone J; Signorelli C; Wakefield CE; Donoghoe M; Johnston K; Bell R; Cohn RJ, 2022, 'The 'ENGAGE' program: Effective childhood cancer survivorship care', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 80 - 80, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000871956500081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Body A; Wakefield C; Luong VTT; Donoghoe M; Fuentes Bolanos NA; Anazodo A; Ho C; Grech L; Ahern ES; Segelov E, 2022, 'Patient-reported toxicity and quality of life following Sars-CoV-2 vaccination in adults and children with cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. LBA12068 - LBA12068, http://dx.doi.org/10.1200/jco.2022.40.17_suppl.lba12068

Robertson E; Wakefield C; Cohn R; Robert B; Donoghoe M; Ziegler D; Fardell J; Mitchell R; O'Brien T, 2019, 'Delta: A Parent and Patient Decision Aid to Support Clinical Trial Decision-Making in Childhood Cancer', in PEDIATRIC BLOOD & CANCER, WILEY, Vol. 66, pp. S118 - S118, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488458001090&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Barbour A; O'Rourke N; Chandrasegaram MD; Chua YJ; Kench J; Samra JS; Pavlakis N; Haghighi KS; Yip S; Fawcett J; Donoghoe M; Walker K; Burge ME; Gananadha S; Harris M; Aghmesheh M; Joubert WL; Gebski V; Simes J; Goldstein D, 2015, 'A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 33, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.4115

Preprints

Body A; Donoghoe M; Lal L; Wakefield C; Ahern ES; Anazodo A; Fuentes Bolanos NA; Padhye B; Downie P; Opat S; Hamad N; Leahy MF; Milch V; Segelov E, 2024, Vaccine beliefs, adverse effects, and quality of life in patients with cancer undergoing routine COVID-19 vaccination, http://dx.doi.org/10.1101/2024.06.02.24308345

Spitzer H; Berry S; Donoghoe M; Pelkmans L; Theis F, 2022, Learning consistent subcellular landmarks to quantify changes in multiplexed protein maps, http://dx.doi.org/10.1101/2022.05.07.490900

Back to profile page